Who qualifies for Vascepa?
Vascepa (icosapent ethyl) is FDA-approved to reduce cardiovascular risk in adults with elevated triglycerides (≥150 mg/dL) who have either established cardiovascular disease or diabetes plus at least two additional risk factors, while already on statin therapy and maximum tolerated dose. Patients must also have LDL cholesterol controlled (≥41 mg/dL on statins or ≥100 mg/dL on non-statins). It's not approved for all high triglycerides cases—only those meeting these criteria.[1]
Common exclusions and contraindications
Vascepa is contraindicated in patients with known hypersensitivity to icosapent ethyl or its components. It's not recommended during pregnancy (Category C; limited data, potential fetal risk) or breastfeeding (excreted in milk). Use caution in patients with bleeding disorders, liver impairment, or those on anticoagulants/antithrombotics due to increased bleeding risk.[1][2]
Who else might face restrictions?
- Children: Not approved for anyone under 18; safety and efficacy unestablished.
- Kidney issues: No dose adjustment needed for mild-moderate impairment, but data lacking for severe cases.
- Alcohol dependency: Avoid in active cases, as it worsens hypertriglyceridemia.
- Other meds: Potential interactions with fibrates or omega-3s; monitor closely.[1][2]
Patients should consult doctors for personalized eligibility, as off-label use occurs but lacks approval.
[1]: FDA Vascepa Label
[2]: Vascepa Prescribing Information